Gi Dynamics (GIDYL) 10-Q 10 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'GIDYL	'
Entity Registrant Name	'GI DYNAMICS, INC.	'
Entity Central Index Key	'0001245791	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	94,795,481

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$61,190	$58,616
Accounts receivable, net	870	660
Inventory	7,485	7,271
Prepaid expenses and other current assets	1,673	1,288
Total current assets	71,218	67,835
Property and equipment, net	1,239	1,490
Total assets	72,457	69,325
Current liabilities:	'	'
Accounts payable	1,141	1,267
Accrued expenses	7,360	4,400
Deferred revenue	659	722
Current portion of long-term debt	'	58
Other current liabilities	62	'
Total current liabilities	9,222	6,447
Deferred rent	205	167
Other liabilities	20	'
Warrants to purchase common stock	62	326
Commitments (Note 10)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value - 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2014 and December 31, 2013	0	0
Common stock	948	801
Additional paid-in capital	247,832	213,305
Accumulated deficit	-185,832	-151,721
Total stockholders' equity	62,948	62,385
Total liabilities and stockholders' equity	72,457	69,325
Class B common stock	'	'
Stockholders' equity:	'	'
Common stock	$0	$0

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	130,000,000	130,000,000
Common stock, shares issued	94,795,481	80,087,717
Common stock, shares outstanding	94,760,481	80,087,717
Class B common stock	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue	$609	$493	$2,355	$1,195
Cost of revenue	393	432	1,846	1,508
Gross profit (loss)	216	61	509	-313
Operating expenses:	'	'	'	'
Research and development	6,833	3,879	19,693	10,567
Sales and marketing	2,412	2,778	7,974	7,943
General and administrative	2,670	1,947	7,276	7,032
Total operating expenses	11,915	8,604	34,943	25,542
Loss from operations	-11,699	-8,543	-34,434	-25,855
Other income (expense):	'	'	'	'
Interest income	41	173	217	320
Interest expense	'	-1	-1	-4
Foreign exchange gain (loss)	-522	491	-95	-694
Remeasurement of warrant liability	69	-223	264	-152
Other income (expense), net	-412	440	385	-530
Loss before income tax expense	-12,111	-8,103	-34,049	-26,385
Income tax expense	19	24	62	82
Net loss	-12,130	-8,127	-34,111	-26,467
Basic and diluted net loss per common share	($0.13)	($0.11)	($0.39)	($0.42)
Weighted-average number of common shares used in basic and diluted net loss per common share	94,760,481	75,445,376	88,365,265	63,497,247
Comprehensive loss	($12,130)	($8,127)	($34,111)	($26,467)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating activities	'	'
Net loss	($34,111)	($26,467)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	485	283
Gain on sale of property and equipment	'	-1
Stock-based compensation expense	3,370	3,074
Remeasurement of warrant liability	-264	152
Changes in operating assets and liabilities:	'	'
Accounts receivable	-210	-597
Prepaid expenses and other current assets	-385	-534
Inventory	-214	-2,377
Accounts payable	-126	-6
Accrued expenses	2,907	-1,207
Deferred revenue	-63	577
Deferred rent	91	126
Net cash used in operating activities	-28,520	-26,977
Investing activities	'	'
Purchases of property and equipment	-234	-1,032
Proceeds from sale of property and equipment	'	1
Change in restricted cash	'	33
Net cash used in investing activities	-234	-998
Financing activities	'	'
Proceeds from exercise of stock options	604	42
Net proceeds from issuance of common stock	30,782	52,515
Payments on long-term debt	-58	-49
Net cash provided by financing activities	31,328	52,508
Net increase in cash and cash equivalents	2,574	24,533
Cash and cash equivalents at beginning of period	58,616	41,481
Cash and cash equivalents at end of period	61,190	66,014
Supplemental cash flow disclosures	'	'
Cash paid for interest	1	3
Income taxes paid	$36	$64

Nature_of_Business

Nature of Business	9 Months Ended
	Sep. 30, 2014
Nature of Business	'
	1. Nature of Business
	GI Dynamics, Inc. (the “Company”) was incorporated on March 24, 2003, as a Delaware corporation, with operations based in Lexington, Massachusetts. The Company designs, develops, and markets medical devices for non-surgical approaches to treating type 2 diabetes and obesity. Since incorporation, the Company has devoted substantially all of its efforts to product commercialization, research and development, business planning, recruiting management and technical staff, acquiring operating assets, and raising capital. The Company began commercial sales of its product, EndoBarrier®, in 2011 and currently operates in one reportable business segment which designs, manufactures and markets medical devices.
	The Company is subject to a number of risks similar to other medical device companies, including, but not limited to, market acceptance of the Company’s products, development by its competitors of new technological innovations, safety and efficacy of the products in clinical trials, the regulatory approval process governing medical devices, raising additional capital and protection of proprietary technology.
	On October 6, 2014, the Company’s Notified Body in the European Union, an organization that has been accredited by a Member State to assess whether a product meets certain preordained standards, has temporarily suspended the Company’s commercial product shipments of the EndoBarrier labeled with a CE Mark, affecting all countries where the Company is currently selling EndoBarrier, pending a review of the Company’s vigilance and reporting systems. A CE Mark is a mandatory conformity marking for certain products sold within the European Economic Area. The suspension of shipments is not a product recall and does not apply to products currently owned by hospitals or distributors, or products required for use in clinical trials. The Company plans to continue its ongoing clinical trial activities, including the pivotal trial currently underway in the United States. In response to the Notified Body’s specific requests for corrective action relating to vigilance and reporting systems, the Company has formally submitted its responses for review by the Notified Body. The Company believes it has remediated the deficiencies in question, but continues to work closely with the governing authorities in Europe to resolve any remaining questions in order to resume product shipments as soon as possible. Meanwhile, the Company is continuing to manufacture its product as the design and manufacturing of the EndoBarrier has not been a subject of the Notified Body’s inquiry and action. As a result of the temporary suspension of commercial product shipments, the Company expects revenue to decrease in the three months ending December 31, 2014 compared to the three months ended September 30, 2014.
	The Company has incurred operating losses since inception and at September 30, 2014, had an accumulated deficit of approximately $185.8 million. At September 30, 2014, the Company had approximately $61.2 million in cash and cash equivalents, which it believes is sufficient to fund its operations through at least September 30, 2015. In September 2011, the Company completed its initial public offering (“IPO”) of common stock in the form of CHESS Depositary Interests (“CDIs”) in Australia. As a result of the IPO and simultaneous private placement in the U.S., the Company raised a total of approximately $72.5 million in proceeds, net of expenses and repayment of $6.0 million of the Company’s Convertible Term Promissory Notes. Additionally, in July and August 2013, the Company sold CDIs on the Australian Securities Exchange (“ASX”) through a private placement and Share Purchase Plan (“SPP”), which raised a total of approximately $52.5 million, net of expenses. In May 2014, the Company raised an additional approximately $30.8 million, net of expenses, when it sold CDIs on the ASX through a private placement.

Summary_of_Significant_Account

Summary of Significant Accounting Policies and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies and Basis of Presentation	'
	2. Summary of Significant Accounting Policies and Basis of Presentation
	The accompanying condensed consolidated financial statements and the related disclosures as of September 30, 2014 and for the three and nine months ended September 30, 2014 and 2013 are unaudited and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s registration statement on Form 10 (“Form 10”). The December 31, 2013 condensed consolidated balance sheet included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP for complete financial statements.
	The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly the Company’s financial position as of September 30, 2014, results of its operations for the three and nine months ended September 30, 2014 and 2013 and its cash flows for the nine months ended September 30, 2014 and 2013. The interim results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.
	The Company’s significant accounting policies are as described in Note 2, Summary of Significant Accounting Policies, in the Company’s Form 10.
	In addition to the consignment-like arrangements described in Note 2 in the Company’s Form 10, in which the Company recognizes revenue when the product is implanted or otherwise consumed and payment is received from the customer, the Company has entered into consignment arrangements in which the Company delivers the product to the customer but retains title to the product until it is implanted or otherwise consumed. In these arrangements, the Company recognizes revenue once it receives proof of third party purchase, usually in the form of a customer purchase order.
	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the accounts of GI Dynamics, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
	Use of Estimates
	The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. On an ongoing basis, the Company’s management evaluates its estimates, including those related to revenue recognition, inventory valuation and related reserves, impairment of long-lived assets, income taxes including the valuation allowance for deferred tax assets, research and development, contingencies and stock-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
	Subsequent Events
	The Company evaluates events occurring after the date of its condensed consolidated balance sheet for potential recognition or disclosure in its condensed consolidated financial statements. There have been no subsequent events other than that disclosed in Note 1 that have occurred through the date the Company issued its condensed consolidated financial statements that require disclosure in or adjustment to its condensed consolidated financial statements.
	Reclassifications
	Certain reclassifications related to the presentation of income tax expense in the condensed consolidated statements of comprehensive loss have been made to prior year amounts to conform with current year presentation. In prior years, income tax expense was included in operating expenses as the amounts were not material.
	New Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its consolidated financial position or results of operations upon adoption.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 will be effective for the Company for reporting periods beginning after December 15, 2016. Early adoption is not permitted. Management is currently evaluating the impact of the pending adoption of ASU 2014-09 on the Company’s consolidated financial statements.

Net_Loss_per_Common_Share

Net Loss per Common Share	9 Months Ended
	Sep. 30, 2014
Net Loss per Common Share	'
	3. Net Loss per Common Share
	Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Potential common stock equivalents are determined using the treasury stock method. For diluted net loss per share purposes, the Company excludes stock options and other stock-based awards, including shares issued as a result of option exercises but which are subject to repurchase by the Company, whose effect would be anti-dilutive from the calculation. During each of the three and nine months ended September 30, 2014 and 2013, common stock equivalents were excluded from the calculation of diluted net loss per common share, as their effect was anti-dilutive due to the net loss incurred. The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September 30, 2014 and 2013, as they would be anti-dilutive:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Warrants to purchase common stock		500,000		500,000		500,000		500,000
	Options to purchase common stock and other stock-based awards		15,419,580		9,642,220		15,419,580		9,642,220
	Total		15,919,580		10,142,220		15,919,580		10,142,220

Common_Stock_Warrants

Common Stock Warrants	9 Months Ended
	Sep. 30, 2014
Common Stock Warrants	'
	4. Common Stock Warrants
	In connection with the Company’s IPO in September 2011, the Company issued warrants in an aggregate amount of 500,000 shares of common stock at an exercise price of A$5.50 per share to the lead manager of the IPO and certain other investors. The warrants will expire on the fifth anniversary of their date of grant. The warrants may be converted on a cashless basis at the option of the holder. The Company has reserved 500,000 shares of common stock related to these warrants.
	The Company accounts for the warrants under Accounting Standards Codification 815, Derivatives and Hedging (“ASC 815”). In accordance with the guidance included in ASC 815, because the Company’s functional currency is the U.S. dollar and the exercise price of the warrants is in Australian dollars, the Company is exposed to currency exchange risk related to the warrants. As a result, the warrants are not considered indexed to the Company’s own stock, and therefore, the warrants are classified as a liability and the fair value of the warrants must be remeasured at each reporting period. At the time the warrants were issued, the Company estimated the fair value of the warrants using the Black-Scholes option pricing model. The Company remeasured the fair value of the warrants at each reporting period using current assumptions and current foreign exchange rates, with changes in value recorded as other income or expense (Note 5).

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value of Financial Instruments	'
	5. Fair Value of Financial Instruments
	The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014 and December 31, 2013, and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value. In general, fair values determined by Level 1 inputs utilize observable inputs such as quoted prices in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, requiring the Company to develop its own assumptions for the asset or liability.
	The following tables present the assets and liabilities the Company has measured at fair value on a recurring basis (in thousands):
					Fair Value Measurements at
					Reporting Date Using
	Description	September 30,			Quoted Prices in			Significant Other		Significant
		2014			Active Markets for			Observable		Unobservable
					Identical Assets			Inputs		Inputs
					(Level 1)			(Level 2)		(Level 3)
	Assets
	Money market funds (included in cash and cash equivalents)	$	41,949		$	41,949		$	—	$	—
	Total assets	$	41,949		$	41,949		$	—	$	—
	Liabilities
	Warrants to purchase common stock	$	62		$	—		$	—	$	62
	Total liabilities	$	62		$	—		$	—	$	62
					Fair Value Measurements at
					Reporting Date Using
	Description	December 31,			Quoted Prices in			Significant Other		Significant
		2013			Active Markets for			Observable		Unobservable
					Identical Assets			Inputs		Inputs
					(Level 1)			(Level 2)		(Level 3)
	Assets
	Money market funds (included in cash and cash equivalents)	$	45,560		$	45,560		$	—	$	—
	Total assets	$	45,560		$	45,560		$	—	$	—
	Liabilities
	Warrants to purchase common stock	$	326		$	—		$	—	$	326
	Total liabilities	$	326		$	—		$	—	$	326
	The assumptions used in the Black-Scholes option pricing model to determine the fair value of the common stock warrants at September 30, 2014 and December 31, 2013 were as follows:
		September 30,			December 31,
		2014			2013
	Exercise price (A$5.50 at current exchange rate)	$	4.81		$	4.92
	Fair value of common stock	$	2.1		$	3.36
	Expected volatility		50.1	%		48.7	%
	Expected term (in years)		1.9			2.7
	Risk-free interest rate		0.6	%		0.7	%
	Expected dividend yield		—	%		—	%
	The following table is a rollforward of the fair value of the warrants, where fair value is determined by Level 3 inputs (in thousands):
	Balance at December 31, 2013		326
	Decrease in fair value of warrants upon remeasurement included in other income (expense)		(264	)
	Balance at September 30, 2014	$	62
	Cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities at September 30, 2014 and December 31, 2013 are carried at amounts that approximate fair value due to their short-term maturities and highly liquid nature of these instruments.

Concentrations_of_Credit_Risk_

Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account	9 Months Ended
	Sep. 30, 2014
Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account	'
	6. Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account
	Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalent balances with high quality financial institutions, and consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s short-term investments potentially subject the Company to concentrations of credit risk. The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to have a rating of not less than A, thereby reducing credit risk concentration.
	Accounts receivable primarily consist of amounts due from customers. The Company’s accounts receivable are with distributors and health care providers in different countries. In light of the current economic state of many foreign countries, the Company continues to monitor the creditworthiness of its customers.
	At September 30, 2014 and December 31, 2013, one distributor accounted for approximately 47% and 49% of the Company’s accounts receivable, respectively. No other customer accounted for greater than 10% of the Company’s accounts receivable at either September 30, 2014 or December 31, 2013.
	The Company grants credit to customers in the normal course of business but generally does not require collateral or any other security to support its receivables. The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding invoices and the overall quality and age of those invoices not individually reviewed. The Company believes that credit risks associated with these customers are not significant. To date, the Company has not had any write-offs of bad debt, and as such, the Company does not have an allowance for doubtful accounts as of September 30, 2014 and December 31, 2013.
	In certain circumstances the Company allows customers to return defective or nonconforming products for credit or replacement products. Defective or nonconforming products typically include those products that resulted in an unsuccessful implant procedure. The Company records an estimate for product returns based upon historical trends. The associated reserve for product returns is included in the Company’s accounts receivable.
	The following table shows the components of the Company’s accounts receivable at September 30, 2014 and December 31, 2013 (in thousands):
		September 30,			December 31,
		2014			2013
	Accounts receivable	$	925		$	688
	Less: allowance for sales returns		(55	)		(28	)
	Total	$	870		$	660

Inventory

Inventory	9 Months Ended
	Sep. 30, 2014
Inventory	'
	7. Inventory
	The Company states inventory at the lower of first-in, first-out cost or market. The Company records a provision for excess, expired, and obsolete inventory based primarily on estimates of forecasted revenues. A significant change in the timing or level of demand for products as compared to forecasted amounts may result in recording additional provisions for excess, expired, and obsolete inventory in the future. When capitalizing inventory, the Company considers factors such as status of regulatory approval, alternative use of inventory, and anticipated commercial use of the product.
	Inventory at September 30, 2014 and December 31, 2013 was as follows (in thousands):
		September 30,		December 31,
		2014		2013
	Finished goods	$	1,057	$	1,010
	Work-in-process		2,345		1,208
	Raw materials		4,083		5,053
	Total	$	7,485	$	7,271
	The Company has entered into consignment arrangements in which the Company delivers the product to the customer but retains title to the product until it is implanted or otherwise consumed. At September 30, 2014, an immaterial amount of the finished goods inventory was at customer locations pursuant to these arrangements.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2014
Property and Equipment	'
	8. Property and Equipment
	Property and equipment consisted of the following (in thousands):
		September 30,			December 31,
		2014			2013
	Laboratory equipment	$	421		$	387
	Computer equipment and software		1,124			1,032
	Office furniture and equipment		290			270
	Construction in process		183			95
	Leasehold improvements		921			921
			2,939			2,705
	Less accumulated depreciation and amortization		(1,700	)		(1,215	)
	Total	$	1,239		$	1,490
	Depreciation and amortization expense of property and equipment was approximately $0.2 million and $0.1 million for the three months ended September 30, 2014 and 2013, respectively. Depreciation and amortization expense of property and equipment was approximately $0.5 million and $0.3 million for the nine months ended September 30, 2014 and 2013, respectively.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Accrued Expenses	'
	9. Accrued Expenses
	Accrued expenses consisted of the following (in thousands):
		September 30,		December 31,
		2014		2013
	Clinical trials	$	3,808	$	1,526
	Payroll and related liabilities		2,302		1,576
	Professional fees		503		630
	Deferred rent, current portion		144		91
	Other		603		577
	Total	$	7,360	$	4,400
	Included in payroll and related liabilities is a total of approximately $0.8 million of separation expenses associated with the termination of our chief commercial officer and chief executive officer which will be paid out through September 2015.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies	'
	10. Commitments and Contingencies
	Lease Commitments
	In June 2013, the Company entered into a noncancelable agreement to sublease 33,339 square feet of office, laboratory and manufacturing space in Lexington, Massachusetts. The sublease commenced in June 2013 and expires in December 2016, subject to earlier termination under certain conditions. Base rent during the initial rent period is approximately $0.6 million per year and increases annually by approximately $17,000. The space was delivered to the Company in June 2013 and rent payments commenced in May 2014. The rent expense, inclusive of the escalating rent payments and free rent period, is recognized on a straight-line basis over the term of the sublease agreement. In accordance with the terms of the sublease agreement, the Company maintains an unsecured letter of credit of approximately $0.2 million securing its obligations under the sublease agreement.
	In March 2012, the Company’s subsidiary, GID Germany GmbH, entered into a noncancelable operating lease for office space in Dusseldorf, Germany. The lease was renewed in September 2013 and was extended through April 2015 and is subject to earlier termination based on certain terms and conditions. The lease will extend automatically for successive twelve-month periods until terminated. The rent expense, inclusive of the free rent periods, is recognized on a straight-line basis over the term of the current lease agreement.
	In July 2013, the Company’s subsidiary, GI Dynamics Australia Pty Ltd, entered into a noncancelable operating lease for office space in Baulkham Hills, Australia. The initial term of the lease was for twelve months, which expired in July 2014. The Company exercised its option to renew the lease and extended the term through July 2015, subject to earlier termination under certain conditions.
	Rent expense on noncancelable operating leases was approximately $0.1 million and $0.2 million for the three months ended September 30, 2014 and 2013, respectively. Rent expense on noncancelable operating leases was approximately $0.4 million for both the nine months ended September 30, 2014 and 2013.
	Future minimum lease payments under noncancelable operating leases at September 30, 2014, are as follows (in thousands):
	Year Ending December 31,
	2014	$	157
	2015		617
	2016		611
	Total	$	1,385
	Litigation
	From time to time, the Company is involved in various legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe that the outcome of any of these ongoing legal matters, individually and in aggregate, will have a material adverse effect on the Company’s financial position.
	Guarantees
	The Company has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees.
	As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid.
	The Company is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate the Company to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain.
	The Company leases office space under non-cancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify its landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain.
	As of September 30, 2014 and December 31, 2013, the Company had not experienced any material losses related to these indemnification obligations and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible. As a result, the Company has not established any related reserves.

Stock_Plans

Stock Plans	9 Months Ended
	Sep. 30, 2014
Stock Plans	'
	11. Stock Plans
	The Company has two stock-based compensation plans under which stock options, restricted and unrestricted stock awards, restricted stock units, and other share-based awards are available for grant to employees, directors and consultants of the Company. At September 30, 2014, there were 713,121 shares available for future grant under both plans.
	Stock-Based Compensation
	In calculating stock-based compensation costs, the Company estimated the fair value of stock options using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of short-lived, exchange-traded options that have no vesting restrictions and are fully transferable. The Company estimates the number of awards that will be forfeited in calculating compensation costs. Such costs are then recognized over the requisite service period of the awards on a straight-line basis.
	Determining the fair value of stock-based awards using the Black-Scholes option-pricing model requires the use of highly subjective assumptions, including the expected term of the award and expected stock price volatility. The weighted-average assumptions used to estimate the fair value of employee stock options using the Black-Scholes option-pricing model were as follows for the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Expected volatility		61	%		64.8	%		61.6	%		64.9	%
	Expected term (in years)		6.05			6.05			6.05			6.05
	Risk-free interest rate		2.1	%		1.8	%		2.1	%		1.1	%
	Expected dividend yield		—	%		—	%		—	%		—	%
	The Company uses historical data to estimate forfeiture rates. The Company’s estimated forfeiture rates were 5% and 2% at September 30, 2014 and 2013, respectively.
	During the three months ended September 30, 2014, the Company modified the terms of stock awards previously granted to an employee upon his change in status from employee to non-employee. The modifications included an extension of the exercise period after the status change with respect to certain of the awards and the extension of the vesting of certain options through the end of his expected service to the Company. These modifications resulted in an immaterial increase in stock-based compensation. The Company accounted for the modifications of stock awards in accordance with the provision of ASC 718, Stock Compensation (“ASC 718”). Stock awards that are modified and continue to vest when an employee has a change in employment status are subject to periodic revaluation over their vesting terms.
	Stock-based compensation is reflected in the condensed consolidated statements of comprehensive loss as follows for the three and nine months ended September 30, 2014 and 2013 (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Cost of revenue	$	33		$	17		$	93		$	52
	Research and development		330			235			970			609
	Sales and marketing		376			342			1,202			1,079
	General and administrative		423			301			1,105			1,334
		$	1,162		$	895		$	3,370		$	3,074
	Stock Options
	The following table summarizes share-based activity under the Company’s stock option plans:
		Shares of			Weighted-			Weighted-			Aggregate
		Common			Average			Average			Intrinsic
		Stock			Exercise			Contractual			Value
		Attributable			Price			Life
		to Options
								(in years)			(in thousands)
	Outstanding at December 31, 2013		9,634,547		$	2.59			6.66		$	13,319
	Granted		6,125,089		$	2.68
	Exercised		(1,517,511	)	$	0.4
	Cancelled		(914,985	)	$	4
	Outstanding at September 30, 2014		13,327,140		$	2.78			7.35		$	4,811
	Vested or expected to vest at September 30, 2014		12,949,271		$	2.77			6.86		$	4,803
	Exercisable at September 30, 2014		5,769,829		$	2.54			4.2		$	4,643
	As of September 30, 2014, there was approximately $11.0 million of unrecognized stock-based compensation, net of estimated forfeitures, related to unvested stock option grants under the plans, which is expected to be recognized over a weighted-average period of 3.3 years. The total unrecognized stock-based compensation cost will be adjusted for future changes in estimated forfeitures. The Company also has unrecognized stock-based compensation expense of approximately $0.5 million, net of estimated forfeitures, related to stock options with performance-based vesting criteria that are not considered probable of achievement as of September 30, 2014; therefore the Company has not yet begun to recognize the expense on these awards.
	The weighted-average grant date fair value of options granted during the three months ended September 30, 2014 and 2013 was $1.23 and $2.13, respectively, and $1.53 and $1.96 for the nine months ended September 30, 2014 and 2013, respectively. The total intrinsic value of options exercised during the three months ended September 30, 2014 and 2013 was approximately none and $32,000, respectively, and approximately $4.3 million and $0.4 million for the nine months ended September 30, 2014 and 2013, respectively. The intrinsic value represents the difference between the fair value of the Company’s common stock on the date of exercise and the exercise price of the stock option. Cash received from option exercises during the three months ended September 30, 2014 and 2013 was approximately $82,000 and $6,000, respectively, and approximately $0.6 million and $42,000 for the nine months ended September 30, 2014 and 2013, respectively. No tax benefits were realized from options and other stock-based payment arrangements during these periods.
	The stock-based compensation plans provide that grantees may have the right to exercise an option prior to vesting. Shares purchased upon the exercise of unvested options will be subject to the same vesting schedule as the underlying options, and are subject to repurchase at the original exercise price by the Company should the grantee discontinue providing services to the Company for any reason, prior to becoming fully vested in such shares. At September 30, 2014, there were 35,000 shares issued pursuant to the exercise of unvested options that remain unvested and subject to repurchase by the Company. The exercise of these shares is not substantive and as a result, the cash paid for the exercise price is considered a deposit or prepayment of the exercise price and is recorded as a liability. Additionally, while, the shares subject to repurchase are included in the legally issued shares, they are excluded from the calculation of outstanding shares. At December 31, 2013, there were no shares subject to repurchase by the Company.
	Restricted Stock Units
	Each restricted stock unit (“RSU”) represents a contingent right to receive one share of the Company’s common stock. RSUs generally vest on a pro-rata basis on each anniversary of the issuance date over four years or vest in equal parts upon the achievement of a product revenue milestone and a regulatory milestone. There is no consideration payable on the vesting of RSUs issued under the plans. Upon vesting, the RSUs are exercised automatically and settled in shares of the Company’s common stock. In the nine months ended September 30, 2014, the Company awarded a total of 2,095,720 RSUs to employees of the Company.
	The following table summarizes information related to the RSUs and activity in the nine months ended September 30, 2014:
		Number of Units			Weighted-			Aggregate
					Average			Intrinsic
					Contractual			Value
					Life
					(in years)			(in thousands)
	Outstanding at December 31, 2013		—			—		$	—
	Granted		2,095,720
	Vested/Exercised		—
	Cancelled		(38,280	)
	Outstanding at September 30, 2014		2,057,440			5.73		$	4,321
	The aggregate intrinsic value at September 30, 2014 noted in the table above represents the closing price of the Company’s common stock multiplied by the number of RSUs outstanding.
	At September 30, 2014, 1,221,991 of the RSUs outstanding are subject to performance-based vesting criteria as described above.
	The fair value of each RSU award equals the closing price of the Company’s common stock on the date of grant. The weighted average grant date fair value per share of RSUs granted in the three and nine months ended September 30, 2014 was $2.15 and $2.26, respectively.
	As of September 30, 2014, there was approximately $2.9 million of unrecognized stock-based compensation expense, net of estimated forfeitures, related to non-vested RSU awards. This expense is expected to be recognized over a weighted average period of 2.7 years. The Company also has unrecognized stock-based compensation expense of approximately $1.3 million, net of estimated forfeitures, related to RSUs with performance-based vesting criteria that are not considered probable of achievement as of September 30, 2014; therefore the Company has not yet begun to recognize the expense on these awards.

Segment_Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2014
Segment Reporting	'
	12. Segment Reporting
	Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company has one reportable segment which designs, develops, manufactures and markets medical devices for non-surgical approaches to treating type 2 diabetes and obesity.
	Geographic Reporting
	All the Company’s revenue is attributable to customers outside the U.S. The Company is dependent on favorable economic and regulatory environments for its products. Products are sold to customers located in Europe, the Middle East, Australia and South America and sales are attributed to a country or region based on the location of the customer to whom the products are sold.
	At September 30, 2014, long-lived assets, comprised of property and equipment, of approximately $1.2 million are primarily held in the U.S. Total long-lived assets held outside of the U.S. represent less than 1% of total long-lived assets.
	Product sales by geographic location for the three and nine months ended September 30, 2014 and 2013 are listed in the table below (in thousands).
			Three Months Ended				Nine Months Ended
			September 30,				September 30,
			2014		2013		2014		2013
	Germany		$	272	$	93	$	764	$	325
	Netherlands			*		78		*		138
	Other Europe			133		94		689		191
	Qatar			—		118		—		118
	Israel			*		50		*		*
	Other Middle East			14		—		242		71
	Chile			63		49		284		206
	Australia			127		11		376		146
	Total Revenue		$	609	$	493	$	2,355	$	1,195
	*	Revenue associated with the individual country is less than 10% of total revenue for the period and is included in the appropriate regional line.
	Major Customers
	In the three months ended September 30, 2014, one health care provider accounted for approximately 13% of the Company’s revenue and one distributor accounted for approximately 10% of the Company’s revenue. In the three months ended September 30, 2013, two health care providers accounted for approximately 24% and 16%, respectively, and two distributors each accounted for approximately 10% of the Company’s revenue. No other customer accounted for greater than 10% of the Company’s revenue during the three months ended September 30, 2014 and 2013.
	In the nine months ended September 30, 2014, one distributor accounted for approximately 11% of the Company’s revenue. In the nine months ended September 30, 2013, one distributor accounted for approximately 17% of the Company’s revenue and two health care providers accounted for approximately 12% and 10%, respectively, of the Company’s revenue. No other customer accounted for greater than 10% of the Company’s revenue during the nine months ended September 30, 2014 and 2013.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2014
Principles of Consolidation	'
	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the accounts of GI Dynamics, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in accordance with GAAP requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. On an ongoing basis, the Company’s management evaluates its estimates, including those related to revenue recognition, inventory valuation and related reserves, impairment of long-lived assets, income taxes including the valuation allowance for deferred tax assets, research and development, contingencies and stock-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Subsequent Events	'
	Subsequent Events
	The Company evaluates events occurring after the date of its condensed consolidated balance sheet for potential recognition or disclosure in its condensed consolidated financial statements. There have been no subsequent events other than that disclosed in Note 1 that have occurred through the date the Company issued its condensed consolidated financial statements that require disclosure in or adjustment to its condensed consolidated financial statements.
Reclassifications	'
	Reclassifications
	Certain reclassifications related to the presentation of income tax expense in the condensed consolidated statements of comprehensive loss have been made to prior year amounts to conform with current year presentation. In prior years, income tax expense was included in operating expenses as the amounts were not material.
New Accounting Pronouncements	'
	New Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are not yet effective will not have a material effect on its consolidated financial position or results of operations upon adoption.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which stipulates that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 will be effective for the Company for reporting periods beginning after December 15, 2016. Early adoption is not permitted. Management is currently evaluating the impact of the pending adoption of ASU 2014-09 on the Company’s consolidated financial statements.

Net_Loss_per_Common_Share_Tabl

Net Loss per Common Share (Tables)	9 Months Ended
	Sep. 30, 2014
Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares	'
	The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares outstanding as of September 30, 2014 and 2013, as they would be anti-dilutive:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Warrants to purchase common stock		500,000		500,000		500,000		500,000
	Options to purchase common stock and other stock-based awards		15,419,580		9,642,220		15,419,580		9,642,220
	Total		15,919,580		10,142,220		15,919,580		10,142,220

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value of Assets and Liabilities Measured on Recurring Basis	'
	The following tables present the assets and liabilities the Company has measured at fair value on a recurring basis (in thousands):
					Fair Value Measurements at
					Reporting Date Using
	Description	September 30,			Quoted Prices in			Significant Other		Significant
		2014			Active Markets for			Observable		Unobservable
					Identical Assets			Inputs		Inputs
					(Level 1)			(Level 2)		(Level 3)
	Assets
	Money market funds (included in cash and cash equivalents)	$	41,949		$	41,949		$	—	$	—
	Total assets	$	41,949		$	41,949		$	—	$	—
	Liabilities
	Warrants to purchase common stock	$	62		$	—		$	—	$	62
	Total liabilities	$	62		$	—		$	—	$	62
					Fair Value Measurements at
					Reporting Date Using
	Description	December 31,			Quoted Prices in			Significant Other		Significant
		2013			Active Markets for			Observable		Unobservable
					Identical Assets			Inputs		Inputs
					(Level 1)			(Level 2)		(Level 3)
	Assets
	Money market funds (included in cash and cash equivalents)	$	45,560		$	45,560		$	—	$	—
	Total assets	$	45,560		$	45,560		$	—	$	—
	Liabilities
	Warrants to purchase common stock	$	326		$	—		$	—	$	326
	Total liabilities	$	326		$	—		$	—	$	326
Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Common Stock Warrants	'
	The assumptions used in the Black-Scholes option pricing model to determine the fair value of the common stock warrants at September 30, 2014 and December 31, 2013 were as follows:
		September 30,			December 31,
		2014			2013
	Exercise price (A$5.50 at current exchange rate)	$	4.81		$	4.92
	Fair value of common stock	$	2.1		$	3.36
	Expected volatility		50.1	%		48.7	%
	Expected term (in years)		1.9			2.7
	Risk-free interest rate		0.6	%		0.7	%
	Expected dividend yield		—	%		—	%
Rollforward of Fair Value of Warrants	'
	The following table is a rollforward of the fair value of the warrants, where fair value is determined by Level 3 inputs (in thousands):
	Balance at December 31, 2013		326
	Decrease in fair value of warrants upon remeasurement included in other income (expense)		(264	)
	Balance at September 30, 2014	$	62

Concentrations_of_Credit_Risk_1

Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account (Tables)	9 Months Ended
	Sep. 30, 2014
Components of Company's Accounts Receivable	'
	The following table shows the components of the Company’s accounts receivable at September 30, 2014 and December 31, 2013 (in thousands):
		September 30,			December 31,
		2014			2013
	Accounts receivable	$	925		$	688
	Less: allowance for sales returns		(55	)		(28	)
	Total	$	870		$	660

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory	'
	Inventory at September 30, 2014 and December 31, 2013 was as follows (in thousands):
		September 30,		December 31,
		2014		2013
	Finished goods	$	1,057	$	1,010
	Work-in-process		2,345		1,208
	Raw materials		4,083		5,053
	Total	$	7,485	$	7,271

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property and Equipment	'
	Property and equipment consisted of the following (in thousands):
		September 30,			December 31,
		2014			2013
	Laboratory equipment	$	421		$	387
	Computer equipment and software		1,124			1,032
	Office furniture and equipment		290			270
	Construction in process		183			95
	Leasehold improvements		921			921
			2,939			2,705
	Less accumulated depreciation and amortization		(1,700	)		(1,215	)
	Total	$	1,239		$	1,490

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Accrued Expenses	'
	Accrued expenses consisted of the following (in thousands):
		September 30,		December 31,
		2014		2013
	Clinical trials	$	3,808	$	1,526
	Payroll and related liabilities		2,302		1,576
	Professional fees		503		630
	Deferred rent, current portion		144		91
	Other		603		577
	Total	$	7,360	$	4,400

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2014
Future Minimum Lease Payments under Noncancelable Operating Leases	'
	Future minimum lease payments under noncancelable operating leases at September 30, 2014, are as follows (in thousands):
	Year Ending December 31,
	2014	$	157
	2015		617
	2016		611
	Total	$	1,385

Stock_Plans_Tables

Stock Plans (Tables)	9 Months Ended
	Sep. 30, 2014
Weighted-average Assumptions used to Estimate Fair Value of Stock Options	'
	The weighted-average assumptions used to estimate the fair value of employee stock options using the Black-Scholes option-pricing model were as follows for the three and nine months ended September 30, 2014 and 2013:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Expected volatility		61	%		64.8	%		61.6	%		64.9	%
	Expected term (in years)		6.05			6.05			6.05			6.05
	Risk-free interest rate		2.1	%		1.8	%		2.1	%		1.1	%
	Expected dividend yield		—	%		—	%		—	%		—	%
Stock-Based Compensation	'
	Stock-based compensation is reflected in the condensed consolidated statements of comprehensive loss as follows for the three and nine months ended September 30, 2014 and 2013 (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Cost of revenue	$	33		$	17		$	93		$	52
	Research and development		330			235			970			609
	Sales and marketing		376			342			1,202			1,079
	General and administrative		423			301			1,105			1,334
		$	1,162		$	895		$	3,370		$	3,074
Share-Based Activity	'
	The following table summarizes share-based activity under the Company’s stock option plans:
		Shares of			Weighted-			Weighted-			Aggregate
		Common			Average			Average			Intrinsic
		Stock			Exercise			Contractual			Value
		Attributable			Price			Life
		to Options
								(in years)			(in thousands)
	Outstanding at December 31, 2013		9,634,547		$	2.59			6.66		$	13,319
	Granted		6,125,089		$	2.68
	Exercised		(1,517,511	)	$	0.4
	Cancelled		(914,985	)	$	4
	Outstanding at September 30, 2014		13,327,140		$	2.78			7.35		$	4,811
	Vested or expected to vest at September 30, 2014		12,949,271		$	2.77			6.86		$	4,803
	Exercisable at September 30, 2014		5,769,829		$	2.54			4.2		$	4,643
Restricted Stock Units and Activity	'
	The following table summarizes information related to the RSUs and activity in the nine months ended September 30, 2014:
		Number of Units			Weighted-			Aggregate
					Average			Intrinsic
					Contractual			Value
					Life
					(in years)			(in thousands)
	Outstanding at December 31, 2013		—			—		$	—
	Granted		2,095,720
	Vested/Exercised		—
	Cancelled		(38,280	)
	Outstanding at September 30, 2014		2,057,440			5.73		$	4,321

Segment_Reporting_Tables

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2014
Product Sales by Geographic Location	'
	Product sales by geographic location for the three and nine months ended September 30, 2014 and 2013 are listed in the table below (in thousands).
			Three Months Ended				Nine Months Ended
			September 30,				September 30,
			2014		2013		2014		2013
	Germany		$	272	$	93	$	764	$	325
	Netherlands			*		78		*		138
	Other Europe			133		94		689		191
	Qatar			—		118		—		118
	Israel			*		50		*		*
	Other Middle East			14		—		242		71
	Chile			63		49		284		206
	Australia			127		11		376		146
	Total Revenue		$	609	$	493	$	2,355	$	1,195
	*	Revenue associated with the individual country is less than 10% of total revenue for the period and is included in the appropriate regional line.

Nature_of_Business_Additional_

Nature of Business - Additional Information (Detail) (USD $)	1 Months Ended		2 Months Ended	9 Months Ended
	31-May-14	Sep. 30, 2011	Aug. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
				Segment
Nature Of Operations [Line Items]	'	'	'	'	'	'	'
Number of reportable segments	'	'	'	1	'	'	'
Accumulated deficit	'	'	'	($185,832,000)	($151,721,000)	'	'
Cash and cash equivalents	'	'	'	61,190,000	58,616,000	66,014,000	41,481,000
Proceeds from issuance of shares	30,800,000	72,500,000	52,500,000	'	'	'	'
Repayment of convertible term promissory notes	'	$6,000,000	'	'	'	'	'

Potentially_Dilutive_Securitie

Potentially Dilutive Securities Excluded from Computation of Diluted Weighted Average Shares (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share	15,919,580	10,142,220	15,919,580	10,142,220
Warrant	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share	500,000	500,000	500,000	500,000
Options to purchase common stock and other stock-based awards	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share	15,419,580	9,642,220	15,419,580	9,642,220

Common_Stock_Warrants_Addition

Common Stock Warrants - Additional Information (Detail) (AUD)	Sep. 30, 2011
Class of Warrant or Right [Line Items]	'
Common stock warrants, shares issued in connection with IPO	500,000
Common stock warrant, exercise price	5.5
Common stock warrant, share reserved	500,000

Fair_Value_of_Assets_and_Liabi

Fair Value of Assets and Liabilities Measured on Recurring Basis (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrants to purchase common stock	$62	$326
Fair Value, Measurements, Recurring	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	41,949	45,560
Warrants to purchase common stock	62	326
Total liabilities	62	326
Fair Value, Measurements, Recurring | Money Market Funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	41,949	45,560
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	41,949	45,560
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	41,949	45,560
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrants to purchase common stock	62	326
Total liabilities	$62	$326

Assumptions_used_in_BlackSchol

Assumptions used in Black-Scholes Option Pricing Model to Determine the Fair Value of Common Stock Warrants (Detail) (Warrant)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	AUD	USD ($)	AUD
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Exercise price	$4.81	5.5	$4.92	5.5
Fair value of common stock	$2.10	'	$3.36	'
Expected volatility	50.10%	50.10%	48.70%	48.70%
Expected term	'1 year 10 months 24 days	'1 year 10 months 24 days	'2 years 8 months 12 days	'2 years 8 months 12 days
Risk-free interest rate	0.60%	0.60%	0.70%	0.70%
Expected dividend yield	'	'	'	'

Assumptions_used_in_BlackSchol1

Assumptions used in Black-Scholes Option Pricing Model to Determine the Fair Value of Common Stock Warrants (Parenthetical) (Detail) (Warrant)	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2013
	USD ($)	AUD	USD ($)	AUD
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Exercise price	$4.81	5.5	$4.92	5.5

Rollforward_of_Fair_Value_of_W

Rollforward of Fair Value of Warrants (Detail) (Warrant, USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Warrant	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Beginning balance	$326
Decrease in fair value of warrants upon remeasurement included in other income (expense)	-264
Ending balance	$62

Concentrations_of_Credit_Risk_2

Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account - Additional Information (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
	Distributor	Distributor
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Allowance for doubtful accounts	0	0
Accounts Receivable | Credit Concentration Risk | Distributors	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Number of customers	1	1
Concentration risk percentage	47.00%	49.00%
Accounts Receivable | Credit Concentration Risk | Other Customer	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Number of customers	0	0

Components_of_Companys_Account

Components of Company's Accounts Receivable (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'
Accounts receivable	$925	$688
Less: allowance for sales returns	-55	-28
Total	$870	$660

Inventory_Detail

Inventory (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Finished goods	$1,057	$1,010
Work-in-process	2,345	1,208
Raw materials	4,083	5,053
Total	$7,485	$7,271

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment gross	$2,939	$2,705
Less accumulated depreciation and amortization	-1,700	-1,215
Total	1,239	1,490
Laboratory equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment gross	421	387
Computer equipment and software	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment gross	1,124	1,032
Office furniture and equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment gross	290	270
Construction in process	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment gross	183	95
Leasehold Improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and equipment gross	$921	$921

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'
Depreciation and amortization	$200	$100	$485	$283

Accrued_Expenses_Detail

Accrued Expenses (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Line Items]	'	'
Clinical trials	$3,808	$1,526
Payroll and related liabilities	2,302	1,576
Professional fees	503	630
Deferred rent, current portion	144	91
Other	603	577
Total	$7,360	$4,400

Accrued_Expenses_Additional_in

Accrued Expenses - Additional information (Detail) (Chief Commercial Officer and Chief Executive Officer, USD $)	Sep. 30, 2014
In Millions, unless otherwise specified
Chief Commercial Officer and Chief Executive Officer	'
Accrued Liabilities [Line Items]	'
Payroll and related liabilities	$0.80

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
	sqft
Loss Contingencies [Line Items]	'	'	'	'	'
Rentable area of leased premises	33,339	'	'	'	'
Annual base rent under lease	$600,000	'	'	'	'
Annual increase to base rent	17,000	'	'	'	'
Letter of credit	200,000	'	'	'	'
Rent expense	'	$100,000	$200,000	$400,000	$400,000

Future_Minimum_Lease_Payments_

Future Minimum Lease Payments Under Noncancelable Operating Leases (Detail) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Operating Leased Assets [Line Items]	'
2014	$157
2015	617
2016	611
Total	$1,385

Stock_Plans_Additional_Informa

Stock Plans - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
	CompensationPlan		CompensationPlan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of stock-based compensation plans	2	'	2	'	'
Shares available for future grants	713,121	'	713,121	'	'
Estimated forfeiture rates	'	'	5.00%	2.00%	'
Unrecognized stock-based compensation	$11,000,000	'	$11,000,000	'	'
Weighted-average grant date fair value of options granted	$1.23	$2.13	$1.53	$1.96	'
Option exercised total intrinsic value	0	32,000	4,300,000	400,000	'
Proceeds from exercise of stock options	82,000	6,000	604,000	42,000	'
Share issued pursuant to exercise of unvested options	35,000	'	35,000	'	0
Restricted Stock Units (RSUs)	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Recognized weighted-average period years	'	'	'2 years 8 months 12 days	'	'
Number of shares of common stock to be received, per restricted stock unit	1	'	1	'	'
Award vesting period	'	'	'4 years	'	'
Shares granted to employees	'	'	2,095,720	'	'
Restricted stock units outstanding	2,057,440	'	2,057,440	'	'
Weighted average grant date fair value per share	$2.15	'	$2.26	'	'
Unrecognized stock based compensation	2,900,000	'	2,900,000	'	'
Stock Option	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Recognized weighted-average period years	'	'	'3 years 3 months 18 days	'	'
Performance Shares	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Unrecognized stock-based compensation	500,000	'	500,000	'	'
Restricted stock units outstanding	1,221,991	'	1,221,991	'	'
Unrecognized stock based compensation	$1,300,000	'	$1,300,000	'	'

Weightedaverage_Assumptions_us

Weighted-average Assumptions used to Estimate Fair Value of Stock Options (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected volatility	61.00%	64.80%	61.60%	64.90%
Expected term (in years)	'6 years 18 days	'6 years 18 days	'6 years 18 days	'6 years 18 days
Risk-free interest rate	2.10%	1.80%	2.10%	1.10%
Expected dividend yield	'	'	'	'

StockBased_Compensation_Reflec

Stock-Based Compensation Reflected in Condensed Consolidated Statements of Comprehensive Loss (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$1,162	$895	$3,370	$3,074
Cost of revenue	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	33	17	93	52
Research and Development Expense	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	330	235	970	609
Sales and marketing	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	376	342	1,202	1,079
General and Administrative Expense	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$423	$301	$1,105	$1,334

ShareBased_Activity_Detail

Share-Based Activity (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Options	'	'
Outstanding, beginning balance	9,634,547	'
Granted	6,125,089	'
Exercised	-1,517,511	'
Cancelled	-914,985	'
Outstanding, ending balance	13,327,140	9,634,547
Vested or expected to vest at September 30, 2014	12,949,271	'
Exercisable at September 30, 2014	5,769,829	'
Weighted Average Exercise Price	'	'
Outstanding, beginning balance	$2.59	'
Granted	$2.68	'
Exercised	$0.40	'
Cancelled	$4	'
Outstanding, ending balance	$2.78	$2.59
Vested or expected to vest at September 30, 2014	$2.77	'
Exercisable at September 30, 2014	$2.54	'
Weighted Average Contractual Life (in Years)	'	'
Outstanding at end of period	'7 years 4 months 6 days	'6 years 7 months 28 days
Vested or expected to vest at September 30, 2014	'6 years 10 months 10 days	'
Exercisable at September 30, 2014	'4 years 2 months 12 days	'
Aggregate Intrinsic Value	'	'
Outstanding at end of period	$4,811	$13,319
Vested or expected to vest at September 30, 2014	4,803	'
Exercisable at September 30, 2014	$4,643	'

Restricted_Stock_Units_and_Act

Restricted Stock Units and Activity (Detail) (Restricted Stock Units (RSUs), USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014
Restricted Stock Units (RSUs)	'
Number of Units	'
Granted	2,095,720
Vested/Exercised	'
Cancelled	-38,280
Outstanding, ending balance	2,057,440
Weighted Average Contractual Life (in years)	'
Outstanding at end of period	'5 years 8 months 23 days
Aggregate Intrinsic Value	'
Outstanding, ending balance	$4,321

Segment_Reporting_Additional_I

Segment Reporting - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
	Customer	Customer	Customer	Customer
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Number of reportable segments	'	'	1	'
Long-lived assets	1.2	'	1.2	'
Sales Revenue, Net | Distributors	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Number of customers	1	2	1	1
Concentration risk percentage	10.00%	10.00%	11.00%	17.00%
Sales Revenue, Net | Health Care Providers	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Number of customers	1	2	'	2
Sales Revenue, Net | Health Care Provider One	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Concentration risk percentage	13.00%	24.00%	'	12.00%
Sales Revenue, Net | Health Care Provider Two	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Concentration risk percentage	'	16.00%	'	10.00%
Sales Revenue, Net | Other Customer	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Number of customers	0	0	0	0
Maximum	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Total long-lived assets held outside of the U.S	1.00%	'	1.00%	'

Product_Sales_by_Geographic_Lo

Product Sales by Geographic Location (Detail) (USD $)	3 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013	Sep. 30, 2014		Sep. 30, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'	'		'
Revenue	$609		$493	$2,355		$1,195
Germany	'		'	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'	'		'
Revenue	272		93	764		325
Netherlands	'		'	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'	'		'
Revenue	'	[1]	78	'	[1]	138
Other Europe	'		'	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'	'		'
Revenue	133		94	689		191
Qatar	'		'	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'	'		'
Revenue	'		118	'		118
ISRAEL	'		'	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'	'		'
Revenue	'	[1]	50	'	[1]	'	[1]
Other Middle East	'		'	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'	'		'
Revenue	14		'	242		71
Chile	'		'	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'	'		'
Revenue	63		49	284		206
Australia	'		'	'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'	'		'
Revenue	$127		$11	$376		$146
[1]	Revenue associated with the individual country is less than 10% of total revenue for the period and is included in the appropriate regional line.